大分割部分乳房再照射在保乳方式治疗乳腺癌局部复发中的价值
本研究评估对乳腺癌局部复发患者行重复保乳手术后,采用大分割调强放疗进行部分乳房再照射(re-PBI)的结局。2012年5月至2021年5月共70例患者接受re-PBI,中位随访6.3年,8年局部控制累积率4%,8年无病生存率76%、乳腺癌特异生存率90%、总生存率90%。作者认为re-PBI是替代乳房切除术的可行选择,局部控制可接受、毒性谱可接受,但需长期随访以更好理解复发模式并巩固其临床地位。
要点
- 70例保乳术后局部复发患者接受重复保乳手术+大分割调强re-PBI,8年第二局部复发累积率4%。
- 8年无病生存率76%、乳腺癌特异生存率90%、总生存率90%。
- 51例评估慢性毒性者中4%出现3级纤维化;46例评估美容效果者中仅略高于60%为良好/极好。
核心结论
- 作者认为,重复保乳手术后行re-PBI在局部控制方面是替代乳房切除术的可行选择,毒性谱可接受。
- 作者指出长期随访对于更好理解复发模式并巩固re-PBI在临床实践中的地位至关重要。
研究设计与样本
- 单臂研究,2012年5月至2021年5月共纳入70例乳腺癌局部复发后接受重复保乳手术的患者。
- 采用螺旋或步进式调强放疗行部分乳房再照射,总剂量37.05 Gy,分13次,2.5周内完成。
- 评估第二局部复发累积发生率、毒性、无病生存、乳腺癌特异生存和总生存。
主要发现
- 中位随访6.3年(四分位1-3,4.0-8.1年);首次局部复发时中位年龄62岁;原发乳腺癌至首次局部复发中位间隔12.4年(范围1.6-26.7年)。
- 首次局部复发为Luminal A样者占41%,中位大小0.8 cm。
- 随访期间18例(26%)出现后续事件:3例第二局部复发(8年累积率4%)、3例区域淋巴结复发、7例远处转移、5例其他原发肿瘤。
- 8年无病生存率76%、乳腺癌特异生存率90%、总生存率90%。
- 多因素分析中,3级和广泛导管内成分是无病生存的独立预测因素。
关键数值与推荐
- 再照射方案为37.05 Gy分13次,2.5周内完成,采用调强放疗(螺旋或步进式)。
- 8年第二局部复发累积率为4%。
- 8年无病生存率76%、乳腺癌特异生存率90%、总生存率90%。
- 慢性毒性中3级纤维化占4%;美容效果良好/极好仅略高于60%。
临床怎么用
- 作者认为,重复保乳手术后行re-PBI在局部控制方面是替代乳房切除术的可行选择,毒性谱可接受。
- 作者指出,长期随访对于更好理解复发模式并巩固re-PBI在临床实践中的地位至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the outcome of partial breast reirradiation (re-PBI) with intensity modulated radiation therapy using a hypofractionated scheme for breast cancer (BC) local relapse (LR) operated on with repeat breast-conservative surgery. METHODS AND MATERIALS: Intensity modulated radiation therapy-based re-PBI was performed using either helical or step-and-shoot modality to deliver 37.05 Gy in 13 fractions in 2.5 weeks. Cumulative incidence of second LR, toxicity, disease-free survival (DFS), BC-specific survival, and overall survival were evaluated. RESULTS: Between May 2012 and May 2021, 70 patients had re-PBI. The median follow-up (FU) was 6.3 years (quartiles 1-3, 4.0-8.1.). The median age at first LR was 62 years. The median primary BC first LR interval was 12.4 years (range, 1.6-26.7 years). Luminal A-like first LR accounted for 41% of the cases, and the median size was 0.8 cm. During FU, 18 (26%) patients showed a subsequent event: 3 second LRs (corresponding to an 8-year cumulative rate of 4%), 3 regional nodal recurrences, 7 distant metastases, and 5 other primary tumors. At 8 years, DFS, BC-specific survival, and overall survival were 76%, 90%, and 90%, respectively. At multivariate analysis, grade 3 and extensive intraductal components were independent predictors for DFS. For 51 and 46 patients, chronic toxicity and cosmesis were evaluated, respectively: 4% had grade 3 fibrosis, and cosmesis was deemed good/excellent in just >60% of the cases. CONCLUSIONS: Re-PBI after repeat breast-conservative surgery represents a feasible alternative to mastectomy with regard to local control, showing an acceptable toxicity profile. A long-term FU is crucial to better understand the pattern of relapse and consolidate the position of re-PBI in clinical practice.
引用
- Leonardi MC, Arculeo S, Frassoni S, et al. Hypofractionated Partial Breast Reirradiation in the Conservative Retreatment of Breast Cancer Local Recurrence. Pract Radiat Oncol. 2024. PMID: 39069002. doi:10.1016/j.prro.2024.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。